CKCecile Kaplan

Cecile Kaplan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cecile Kaplan has a total of 52 co-authors. Here are the top co-authors by number of shared publications:

  • Vincent Jallu

    Platelet Immunology Laboratory, INTS; DSIMB, INSERM, U665, France

    9 shared publications
  • Gerald Bertrand

    Platelet Immunology Department, French Blood Services of Brittany, Rennes, France

    8 shared publications
  • Frederic Bianchi

    From the Platelet Immunology Laboratory, INTS; DSIMB, INSERM, U665; the Université Paris Diderot, Sorbonne Paris Cité, UMR‐S665; and the Institut National de la Transfusion Sanguine, Paris, France

    5 shared publications
  • Christophe Chenet

    Platelet Immunology Unit INTS Paris France

    4 shared publications
  • Corinne Martageix

    From the Platelet Immunology Unit, INTS, Paris; the Maternity Ward, Centre Hospitalier Universitaire, Tours; and Pediatrics, Centre Hospitalier Régional, Orléans, France

    4 shared publications
  • C. Martageix

    INTS, Platelet Immunology Unit, Paris, France

    3 shared publications

Latest Publications

  • Safe fetal platelet genotyping: new developments

    by Emilie Le Toriellec, Christophe Chenet, Cecile Kaplan

    Background: Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is due to maternal alloimmunization against fetal platelet (PLT) antigens. Antenatal management strategies have been developed to avoid complications such as intracranial hemorrhage. The aim of this study was to set up two reliable, noninvasive fetal genotyping assays to determine the fetal risk in pregnancies in which the father is heterozygous for the offending antigen. This study focused on human PLT antigen (HPA)‐1, the most frequently implicated antigen in FNAIT in Caucasians.Study Design and Methods: Two assays based on cell‐free fetal DNA extracted from maternal blood samples and on real‐time polymerase chain reaction (QPCR) were developed: an allele‐specific QPCR specifically targeting the polymorphic sequence in HPA‐1 and the study of the variation in the high‐resolution melting curve of amplicons containing the polymorphic region.Results: All results from the 49 samples obtained from 29 pregnant women were consistent with expectations. Six women were compatible with their fetuses (three HPA‐1aa women and three HPA‐1bb women), 41 HPA‐1bb women were incompatible with their fetuses, as were two HPA‐1aa women.Conclusion: Two fetal PLT genotyping assays on maternal blood samples proved to be reliable as of 15 weeks of gestation, thereby avoiding invasive techniques such as amniocentesis.


  • The αIIb p.Leu841Met (Cab3a+) polymorphism results in a new human platelet alloantigen involved in neonatal alloimmune thrombocytopenia

    by Vincent Jallu, Gerald Bertrand, Frederic Bianchi, Christophe Chenet, Pierre Poulain, Cecile Kaplan

    BACKGROUND: Fetal‐neonatal alloimmune thrombocytopenia (FNAIT) diagnosis relies on maternofetal incompatibility and alloantibody identification. Genotyping for rare platelet (PLT) polymorphisms allowed the identification of three families with suspected or confirmed maternofetal incompatibility for the αIIb‐c.2614C>A mutation (Halle et al., Transfusion 2008;48:14‐15).STUDY DESIGN AND METHODS: A polymerase chain reaction–sequence‐specific primers amplification assay was designed to genotype the αIIb‐c.2614C>A mutation. HEK293 cells expressing αIIb‐Leu841 or αIIb‐Met841 αIIbβ3 forms were used to probe the reactivity of maternal sera from these families and to study the effects of the substitution on αIIbβ3 expression and functions.RESULTS: Tested by flow cytometry (FCM), one serum sample specifically reacted with αIIb‐Met841 but not with αIIb‐Leu841 αIIbβ3. This specificity revealed the αIIb‐Leu841 polymorphism as a new alloantigen named Cab3a+. Cross‐match testing using FCM also showed the Cab3a+ antigen to be expressed at the PLT surface. As for anti‐human PLT alloantigen (HPA)‐3a (or ‐3b) and anti‐HPA‐9bw, detection of anti‐Cab3a+ alloantibodies appeared difficult and required whole PLT assays when classical monoclonal antibody–specific immobilization of PLT antigen test failed. In our FNAIT set, the immune response to Cab3a+ maternofetal incompatibility could induce severe thrombocytopenias and life‐threatening hemorrhages. The p.Leu841Met substitution has limited effects, if any, on local αIIb structure, preserving both αIIbβ3 expression and functions.CONCLUSION: The Cab3a+ polymorphism is a new rare alloantigen (allelic frequency a+ gene frequencies (up to 8.2%; Halle et al., Transfusion 2008;48:14‐15) and homozygous people are observed.


  • Fetal and neonatal alloimmune thrombocytopenia: from bench to bedside

    by C. Kaplan

    During the recent years considerable advances in the clinical and laboratory diagnosis of alloimmune thrombocytopenia have been done. Feto‐maternal alloimmunization is the commonest cause of cause of severe isolated fetal and neonatal thrombocytopenia. The condition results from maternal immunization against specific fetal platelet antigens (HPA). HPA‐1a is mostly implicated in Caucasians. The diagnosis is usually made at birth when an otherwise “well” term infant exhibits bleeding at delivery or few hours afterwards. The most feared complication of this disorder is the occurrence of intracranial hemorrhage (ICH) as a result of severe thrombocytopenia leading to death or neurological sequels. The diagnosis of alloimmune thrombocytopenia enables appropriate management of the index case and future pregnancies. Due to the recurrence and increasing severity of this condition in subsequent pregnancies with incompatible fetuses, antenatal management has been proposed. Predictive maternal parameters for severe fetal thrombocytopenia and therapy effectiveness are important for the development of non‐ invasive strategy.

  • New K103 β3 allele identified in a context of severe neonatal thrombocytopenia

    by Vincent Jallu, Frederic Bianchi, Gerald Bertrand, Cecile Kaplan

    A new β3 allele was identified in a severe case of neonatal alloimmune thrombocytopenia (A mutation in the β3 coding sequence resulting in a false assignation of the HPA-16b allele by PCR-RFLP. This mutation leads to a Q103K substitution in mature β3. The K103-β3 form of the complex was expressed in HEK-293 cells but did not react with the maternal serum. We have characterized a new rare allele (frequency < 1%) of β3 that yields false HPA-16b genotyping in PCR-RFLP. This new case of false typing assignation emphasizes the necessity to use two genotyping techniques in diagnosis. This particularly applies for rare HPA polymorphisms when PLT phenotyping cannot be used.

  • A new Ser472Asn (Cab2a+) polymorphism localized within the αIIb “thigh” domain is involved in neonatal thrombocytopenia

    by Vincent Jallu, Mathilde Dusseaux, Cecile Kaplan

    BACKGROUND: A new platelet antigen, Cab2a+, was identified in a case of severe neonatal alloimmune thrombocytopenia (< 8 x 109/L) in twins. STUDY DESIGN AND METHODS: Coding sequences of alpha IIb and beta 3 genes from parents were amplified and sequenced. CHO cell lines expressing wild-type or mutated forms of the complex were established to study the role of the mutation in alloimmunization and in alpha IIb beta 3 functions. RESULTS: The father and twins were heterozygous for a single alpha IIb c.1508G > A mutation leading to a Ser472Asn substitution. Immunologic assays with transfected CHO cells revealed the Asn472 form of alpha IIb beta 3 responsible for the Cab2a+ epitope but not an Ala472 form. Using these cells lines we demonstrated that both Ser472Asn and Ser472Ala substitutions produced limited structural alteration as revealed by the reactivity of a panel of anti-alpha IIb beta 3 monoclonal antibodies (MoAbs). Activated Asn472 and Ala472 forms of alpha IIb beta 3 supported 1) binding of soluble fibrinogen and of the ligand mimetic MoAb PAC-1, 2) ligand-induced binding site epitopes exposure (MoAbs AP-5 and D3GP3), and 3) cell aggregation. Adhesion onto adsorbed fibrinogen was conserved and was specifically inhibited by MoAb AP-2 or peptide RGDS. Finally outside-in signaling was not affected. CONCLUSION: We have characterized a new low-frequency alloantigen (< 1%) resulting from the Ser472Asn substitution in alpha IIb and shown this polymorphism to have a limited effect, if any, on the alpha IIb beta 3 complex functions.


  • Human platelet antigen allele frequencies in different Algerian populations

    by H. Brouk, L. Halle, G. Bertrand, F. Z. Neche, H. Ouelaa, C. Kaplan

    The frequencies of human platelet antigens (HPAs) vary between different populations and are a major determinant for the prevalence of HPA alloimmunization and its clinically associated entities. No report on HPA prevalence has previously been published for the Algerian populations which are ethnically diverse. The aim of this study was to determine the HPA allele frequencies in Algerian populations and to identify situations of incompatibility possibly leading to alloimmunization. A total of 485 healthy volunteer Algerian blood donors from different regions and representing different ethnic groups were included. HPA genotyping was determined by polymerase chain reaction‐restriction fragment length polymorphism (PCR‐RFLP) and/or polymerase chain reaction‐sequence specific primer (PCR‐SSP). The HPA‐1 allele frequencies were close to the frequencies found in Caucasian populations. The presence of the molecule human leukocyte antigen (HLA)‐DRB3*0101 (17.9%) increases the risk of alloimmunization. We observed an increase in the frequency of homozygous HPA‐5b, particularly in the population of Annaba (7.61%) and the Mzab population (5.13%). The allele frequency HPA‐2b (0.193–0.147) was similar to that seen in Sub‐Saharan African populations. The high frequency of homozygotic HPA‐2b (Kabyle 5%; Mzab 2.44% and Annaba 2.19%) could increase the risk of alloimmunization. GPIIb Ak mutation (2614C>A) was found in these populations. This study is the first to report on HPA allele frequencies in Algerian populations. High allele frequencies were observed for HPA‐1b (0.209–0.112), HPA‐3b (0.411–0.312) and HPA‐5b (0.217–0.087), leading to a high risk of alloimmunization in this population, especially the Mzab and the population of Annaba. Our results could have some impact in the diagnosis, prevention and treatment of alloimmune thrombocytopenia.


  • αIIbβ3 integrin: new allelic variants in Glanzmann thrombasthenia, effects onITGA2BandITGB3mRNA splicing, expression, and structure-function

    by Vincent Jallu, Mathilde Dusseaux, Simon Panzer, Marie-Françoise Torchet, Nathalie Hezard, Jenny Goudemand, Alexandre G. de Brevern, Cécile Kaplan

    Glanzmann thrombasthenia (GT) is an autosomal recessive inherited bleeding disorder characterized by an impaired platelet aggregation due to defects in integrin αIIbβ3 (ITGA2B, ITGB3), a fibrinogen receptor. Mutations from 24 GT patients and two carriers of various origins, Caucasian, North-African and Asian were characterized. Promoter and exon sequences of αIIb and β3 genes were amplified and directly sequenced. Among 29 identified mutations, 17 new allelic variants resulting from nonsense, missense and deletion/insertion mutations were described. RNA alterations were evaluated by using Web servers. The αIIb p.S926L, p.V903F, and β3 p.C38Y, p.M118R, p.G221D substitutions prevented complex expression at the surface of COS-7 cells by altering the αIIb or the β3 subunit structure. As shown by free energy analyses applied on the resolved structure of αIIbβ3 and structural modeling of the mutant, the p.K253M substitution of β3 helped to define a key role of the K253 in the interaction of the αIIb β-propeller and the β3 β-I domains. finally, the αIIb p.Q595H substitution allowed cell surface expression of the complex but its corresponding c.2800G>T mutation is predicted to alter normal RNA splicing. In conclusion, our study yielded the discovery of 17 new GT allelic variants, revealed the key role of K253 of αIIb for the αIIbβ3 complex formation and provides an additional example of an apparently missense mutation causing a splicing defect. Hum Mutat 30:1–10, 2010.